A recent study validates that combining genetic and clinical data can predict the risk for pulmonary fibrosis in patients ...

FDA has granted orphan drug designation to FS2 (kynurenic acid) for the investigational treatment of idiopathic pulmonary ...

BirchBioMed Inc., a leading clinical stage biopharmaceutical company, expert in the development of products for scarring and other fibrosis-related disorders and autoimmune therapeutics, today ...

United Therapeutics' stock surged after IPF trial results and what future pivotal trials could mean for investors. See here ...

Nerandomilast, a PDE4 inhibitor, has shown significant efficacy in progressive pulmonary fibrosis (PPF), offering an ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening ...

A new proteomic analysis is shedding a fresh light on the cytokine networks fueling idiopathic pulmonary fibrosis (IPF), ...

The most common chronic progressive fibrosing ILD is IPF.1,2 PPF is another form of progressive fibrotic lung disease that ...

Select your location to view local American Lung Association events and news near you.

To kick off National Influenza Vaccination Week (December 1 - 6), the American Heart Association®, American Lung Association®, American Diabetes Association® (ADA) and National Foundation for ...

Individuals in close proximity to care for interstitial lung disease (ILD) did not have significantly improved outcomes than those at a greater distance, based on data from more than 1600 individuals ...

A metro woman was given a few years to live in 2022, after being diagnosed with a serious lung disease. However, thanks to a double lung transplant, she was given a second chance at life.